MPS Powered by Eureka

Forgot your password?

To find the most relevant journal, please insert appropriate keyword to facilitate search.

 

Type keyword

Search Results: CNSNDDT

CNS & Neurological Disorders - Drug Targets

ISSN: 1871-5273 (Print)
eISSN: 1996-3181 (Online)

CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. CNS & Neurological Disorders - Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
Journal Impact Factor : 2.7

Start Submission

Special Issues With Active Call for Papers

Submission closes on: Jan 07, 2025
Heart and Brain Axis Targets in CNS Neurological Disorders

Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose of this special issue is to meticulously explore and elucidate the identification and characterization of therapeutic targets that have the capacity to influence both cardiac... see more

Impact Factor: 2.7
Guest Editor(s): Melis Olcum
Start Submission
Submission closes on: Jan 01, 2025
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia

More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and reversible. Although individuals carrying the APOE E4 gene have a higher risk of Alzheimer’s Dementia, lifestyle is the major risk factor for the development of... see more

Impact Factor: 2.7
Guest Editor(s): Renato Sobral Monteiro-Junior
Start Submission
Submission closes on: Dec 08, 2024
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities

The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive overview of the molecular pathways involved in the pathogenesis of neurodegenerative diseases. 2.Highlight Innovations: Showcase recent advancements in therapeutic interventions targeting pathogenic proteins. 3.Foster Collaboration:... see more

Impact Factor: 2.7
Guest Editor(s): Nitish Bhatia
Co-Guest Editor(s): Dr. Benu George,Monu Yadav
Start Submission